Amgen Dismisses Bone Density Concerns Related to Its New Weight-Loss Drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Bona Magazine1h
Menopause essentials: How dairy can support your health during this time
As women approach and go through menopause, they experience a range of health challenges. One of the most significant aspects ...
Sunita Williams Weight Loss: NASA Astronaut Refutes ‘Rumours’, Says Experiencing Fluid Shift, Exercising Regularly
Indian-origin astronaut Sunita Williams addressed rumours about her extreme weight loss from the International Space Station, ...
StyleBlueprint14h
Health at Every Decade: Risks to Know, Questions to Ask, and More
We spoke to a a primary care physician for tips on how to prioritize our health as we age — from our 30s through our 70s and ...
Zacks.com on MSN16h
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
The science behind health benefts of heavy lifting
Discover the powerful benefits of weightlifting for physical and mental health, from preventing chronic diseases to improving ...
STAT22h
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Bone Densitometers Pipeline Research Report 2024: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
The "Bone Densitometers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" report has been added to ResearchAndMarkets.com ...
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...